Alpha Cognition: Funding, Investors & Team (Sep 2026)
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
Alpha Cognition has raised $47.5M across 3 funding rounds on record, the most recent an undisclosed round of $35.9M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alpha Cognition Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Alpha Cognition Funding Rounds
Alpha Cognition raised $5.1M in an undisclosed round announced in Feb 2023.
3 months later, an undisclosed round of $6.5M was announced in May 2023.
1.5 years later, an undisclosed round of $35.9M was announced in Nov 2024.
Alpha Cognition Founders and Leadership Team
No contact details are on record for this team yet.
Alpha Cognition Funding Compared to Other Biotechnology Startups
Alpha Cognition's latest round of $35.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alpha Cognition in Biotechnology and Vancouver
Companies Similar to Alpha Cognition
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Alpha Cognition Funding FAQs
What does Alpha Cognition do?
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
How much funding has Alpha Cognition raised?
Alpha Cognition has raised $47.5M across 3 rounds on record. The most recent is an undisclosed round of $35.9M announced in Nov 2024.
When did Alpha Cognition last raise funding?
Alpha Cognition's most recent funding round on record is an undisclosed round of $35.9M, announced in Nov 2024.
Who is the CEO of Alpha Cognition?
Jayant Panchal is listed as CEO at Alpha Cognition.
Where is Alpha Cognition headquartered?
Alpha Cognition is based in Vancouver, British Columbia, Canada.
How many employees does Alpha Cognition have?
Alpha Cognition is in the 1-10 employee band.
How does Alpha Cognition's funding compare to other Biotechnology startups?
Alpha Cognition's latest round of $35.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Alpha Cognition Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alpha Cognition is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.